<DOC>
	<DOCNO>NCT02045472</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , immunogenicity pharmacokinetics single escalate dos VIS410 healthy volunteer .</brief_summary>
	<brief_title>A Study VIS410 Assess Safety Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy volunteer Body mass index 18 33 kg/m2 , inclusive Normal lab Volunteers agree use acceptable contraceptive measure Prior receipt antibody biologic therapy History cancer , heart disease , diabetes , respiratory condition ( eg asthma ) , autoimmune disorder , blood dyscrasia Any chronic condition require daily prescription counter medication History previous severe allergic reaction Drug alcohol abuse within previous 12 month Positive serology human immunodeficiency virus ( HIV ) antibody , hepatitis C virus ( HCV ) antibody hepatitis B surface antigen ( HBsAg ) Positive pregnancy test Breast feeding Positive drug alcohol test screening checkin Receipt license vaccine ( within 30 day ) investigational product within 30 day 5 halflives , whichever longer , study product administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>